Zoetis Inc. (NYSE:ZTS) Given Average Recommendation of “Buy” by Analysts

Shares of Zoetis Inc. (NYSE:ZTS) have been assigned an average rating of “Buy” from the nine brokerages that are covering the firm, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $217.11.

Several brokerages recently commented on ZTS. Argus raised shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Piper Sandler upped their price target on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. BTIG Research lifted their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Stifel Nicolaus upped their target price on Zoetis from $180.00 to $200.00 and gave the stock a “buy” rating in a research note on Monday, August 5th. Finally, The Goldman Sachs Group lowered their price target on Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a report on Monday, May 6th.

Zoetis Price Performance

Zoetis stock opened at $180.96 on Friday. The firm has a market capitalization of $82.57 billion, a P/E ratio of 34.87, a PEG ratio of 2.81 and a beta of 0.86. Zoetis has a one year low of $144.80 and a one year high of $201.92. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09. The business has a fifty day moving average price of $178.56 and a 200-day moving average price of $175.08.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, topping the consensus estimate of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The business had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. During the same quarter last year, the company earned $1.41 EPS. The firm’s revenue was up 8.3% compared to the same quarter last year. As a group, equities research analysts forecast that Zoetis will post 5.84 EPS for the current year.

Hedge Funds Weigh In On Zoetis

A number of large investors have recently modified their holdings of ZTS. Webster Bank N. A. raised its stake in shares of Zoetis by 89.1% during the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after acquiring an additional 82 shares in the last quarter. Private Wealth Management Group LLC purchased a new position in Zoetis in the 4th quarter worth $33,000. Quarry LP lifted its stake in Zoetis by 273.2% in the second quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after purchasing an additional 153 shares during the last quarter. Gladius Capital Management LP purchased a new stake in Zoetis during the fourth quarter valued at about $40,000. Finally, Neo Ivy Capital Management bought a new position in shares of Zoetis during the fourth quarter valued at about $40,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.